O	0	4	Long
O	4	5	-
O	5	9	term
O	10	17	Effects
O	18	20	of
B-control	21	29	Moderate
O	30	36	versus
B-intervention	37	41	High
I-intervention	42	51	Durations
I-intervention	52	54	of
I-intervention	55	62	Aerobic
I-intervention	63	71	Exercise
O	72	74	on
O	75	85	Biomarkers
O	86	88	of
O	89	95	Breast
O	96	102	Cancer
O	103	107	Risk
O	107	108	:
O	109	115	Follow
O	115	116	-
O	116	118	up
O	119	121	to
O	122	123	a
O	124	134	Randomized
O	135	145	Controlled
O	146	151	Trial
O	151	152	.

O	153	156	The
O	157	164	optimal
O	165	174	lifestyle
O	175	178	for
O	179	185	breast
O	186	192	cancer
O	193	203	prevention
O	204	208	over
O	209	212	the
O	213	217	long
O	218	222	term
O	223	225	is
O	226	233	unclear
O	233	234	.

O	235	237	We
O	238	243	aimed
O	244	246	to
O	247	256	determine
O	257	264	whether
O	265	267	or
O	268	271	not
O	272	275	the
O	276	282	amount
O	283	285	of
O	286	294	exercise
O	295	305	prescribed
O	306	308	in
O	309	310	a
O	311	315	year
O	315	316	-
O	316	320	long
O	321	329	exercise
O	330	342	intervention
O	343	353	influences
O	354	360	breast
O	361	367	cancer
O	368	377	biomarker
O	378	384	levels
O	385	386	1
O	387	391	year
O	392	397	later
O	397	398	.

O	399	401	We
O	402	411	conducted
O	412	413	a
O	414	416	24
O	416	417	-
O	417	422	month
O	423	429	follow
O	429	430	-
O	430	432	up
O	433	438	study
O	439	440	(
O	440	444	2012
O	444	445	-
O	445	449	2014
O	449	450	)
O	451	453	to
O	454	457	the
O	458	464	Breast
O	465	471	Cancer
O	472	475	and
O	476	484	Exercise
O	485	490	Trial
O	491	493	in
O	494	501	Alberta
O	502	503	(
O	503	507	BETA
O	507	508	)
O	508	509	,
O	510	511	a
O	512	514	12
O	514	515	-
O	515	520	month
O	520	521	,
O	522	525	two
O	525	526	-
O	526	531	armed
O	532	533	(
O	533	534	1
O	534	535	:
O	535	536	1
O	536	537	)
O	537	538	,
O	539	542	two
O	542	543	-
O	543	549	center
O	550	560	randomized
O	561	571	controlled
O	572	577	trial
O	578	580	of
O	581	589	exercise
O	590	592	in
B-total-participants	593	596	400
B-eligibility	597	603	cancer
I-eligibility	603	604	-
I-eligibility	604	608	free
I-eligibility	608	609	,
I-eligibility	610	624	postmenopausal
I-eligibility	625	630	women
O	630	631	.

O	632	635	The
O	636	644	exercise
O	645	657	prescription
O	658	661	was
O	662	670	moderate
O	670	671	-
O	671	679	vigorous
O	680	687	aerobic
O	688	696	exercise
O	696	697	,
O	698	699	5
O	700	704	days
O	704	705	/
O	705	709	week
O	710	711	(
O	711	712	3
O	713	717	days
O	717	718	/
O	718	722	week
O	723	733	supervised
O	733	734	)
O	735	738	for
O	739	741	30
O	742	749	minutes
O	749	750	/
O	750	757	session
O	758	759	(
O	759	767	MODERATE
O	767	768	)
O	769	771	or
O	772	774	60
O	775	782	minutes
O	782	783	/
O	783	790	session
O	791	792	(
O	792	796	HIGH
O	796	797	)
O	797	798	.

O	799	811	Participants
O	812	816	were
O	817	822	asked
O	823	826	not
O	827	829	to
O	830	836	change
O	837	842	their
O	843	848	usual
O	849	853	diet
O	853	854	.

O	855	857	We
O	858	862	used
O	863	869	linear
O	870	875	mixed
O	876	882	models
O	883	885	to
O	886	893	compare
O	894	903	biomarker
O	904	918	concentrations
O	919	920	(
O	920	921	C
O	921	922	-
O	922	930	reactive
O	931	938	protein
O	938	939	,
O	940	947	insulin
O	947	948	,
O	949	956	glucose
O	956	957	,
O	958	962	HOMA
O	962	963	-
O	963	965	IR
O	965	966	,
O	967	974	estrone
O	974	975	,
O	976	979	sex
O	980	987	hormone
O	988	995	binding
O	996	1004	globulin
O	1004	1005	,
O	1006	1011	total
O	1012	1021	estradiol
O	1021	1022	,
O	1023	1026	and
O	1027	1031	free
O	1032	1041	estradiol
O	1041	1042	)
O	1043	1047	over
O	1048	1052	time
O	1053	1054	(
O	1054	1055	0
O	1055	1056	,
O	1057	1059	12
O	1059	1060	,
O	1061	1064	and
O	1065	1067	24
O	1068	1074	months
O	1074	1075	)
O	1076	1078	by
O	1079	1084	group
O	1085	1086	(
O	1086	1094	MODERATE
O	1094	1095	,
O	1096	1100	HIGH
O	1100	1101	)
O	1101	1102	,
O	1103	1108	using
O	1109	1114	group
O	1114	1115	-
O	1115	1119	time
O	1120	1132	interactions
O	1132	1133	.

O	1134	1139	After
O	1140	1142	12
O	1143	1149	months
O	1150	1152	of
O	1153	1155	no
O	1156	1168	intervention
O	1168	1169	,
B-outcome	1170	1172	24
I-outcome	1172	1173	-
I-outcome	1173	1178	month
I-outcome	1179	1186	fasting
I-outcome	1187	1192	blood
I-outcome	1193	1200	samples
O	1201	1205	were
O	1206	1215	available
O	1216	1219	for
O	1220	1222	84
O	1222	1223	.
O	1223	1224	0
O	1224	1225	%
O	1226	1229	and
O	1230	1232	82
O	1232	1233	.
O	1233	1234	5
O	1234	1235	%
O	1236	1238	of
O	1239	1247	MODERATE
O	1248	1251	and
O	1252	1256	HIGH
O	1257	1263	groups
O	1263	1264	,
O	1265	1277	respectively
O	1278	1279	(
O	1279	1280	n
O	1281	1282	=
O	1283	1286	333
O	1286	1287	/
O	1287	1290	400
O	1290	1291	)
O	1291	1292	.

O	1293	1295	We
O	1296	1301	found
O	1302	1304	no
O	1305	1313	evidence
O	1314	1318	that
O	1319	1320	0
O	1321	1323	to
O	1324	1326	24
O	1326	1327	-
O	1328	1330	or
O	1331	1333	12
O	1334	1336	to
O	1337	1339	24
O	1339	1340	-
O	1340	1345	month
B-outcome	1346	1355	biomarker
I-outcome	1356	1363	changes
I-outcome	1364	1372	differed
I-outcome	1373	1386	significantly
O	1387	1394	between
O	1395	1405	randomized
O	1406	1412	groups
O	1413	1414	(
O	1414	1418	HIGH
O	1418	1419	:
O	1419	1427	MODERATE
O	1428	1433	ratio
O	1434	1436	of
O	1437	1441	mean
O	1442	1451	biomarker
O	1452	1458	change
O	1459	1465	ranged
O	1466	1470	from
O	1471	1472	0
O	1472	1473	.
O	1473	1475	97
O	1476	1478	to
O	1479	1480	1
O	1480	1481	.
O	1481	1483	06
O	1483	1484	,
O	1485	1486	P
O	1487	1493	values
O	1494	1495	>
O	1495	1496	0
O	1496	1497	.
O	1497	1499	05
O	1500	1503	for
O	1504	1507	all
O	1507	1508	)
O	1508	1509	.

O	1510	1512	We
O	1513	1518	found
O	1519	1523	more
O	1524	1533	favorable
B-outcome	1534	1543	biomarker
I-outcome	1544	1552	profiles
O	1553	1558	among
O	1559	1571	participants
O	1572	1575	who
O	1576	1587	experienced
O	1588	1595	greater
O	1596	1600	than
O	1601	1604	the
O	1605	1611	median
O	1612	1615	fat
O	1616	1620	loss
O	1621	1627	during
O	1628	1631	the
O	1632	1637	trial
O	1637	1638	.

O	1639	1650	Prescribing
O	1651	1658	aerobic
O	1659	1667	exercise
O	1668	1671	for
O	1672	1675	300
O	1676	1682	versus
O	1683	1686	150
O	1687	1694	minutes
O	1694	1695	/
O	1695	1699	week
O	1700	1703	for
O	1704	1706	12
O	1707	1713	months
O	1714	1716	to
O	1717	1725	inactive
O	1725	1726	,
O	1727	1741	postmenopausal
O	1742	1747	women
O	1748	1751	had
O	1752	1754	no
O	1755	1762	effects
O	1763	1765	on
O	1766	1772	longer
O	1772	1773	-
O	1773	1777	term
O	1778	1788	biomarkers
O	1788	1789	.

O	1790	1798	Exercise
O	1799	1802	may
O	1803	1807	lead
O	1808	1810	to
O	1811	1817	larger
O	1818	1830	improvements
O	1831	1833	in
O	1834	1840	breast
O	1841	1847	cancer
O	1848	1858	biomarkers
O	1859	1864	after
O	1865	1877	intervention
O	1878	1883	among
O	1884	1889	women
O	1890	1893	who
O	1894	1898	also
O	1899	1909	experience
O	1910	1913	fat
O	1914	1918	loss
O	1919	1923	with
O	1924	1932	exercise
O	1932	1933	.
